Royalty Pharma Balance Sheet
NASDAQ: RPRXHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Royalty Pharma financial position
At the end of fiscal 2025, Royalty Pharma reported total assets of $19.62 billion, up 7.7% from a year earlier against total liabilities of $9.91 billion. Shareholders' equity stood at $9.71 billion, or 49.5% of assets. The company held $618.7 million in cash and equivalents against $8.95 billion of debt, a net debt position of $8.33 billion.
The current ratio (current assets divided by current liabilities) was 2.40, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.92.
Summary generated from market data by MetaCap's automated system. Methodology
Royalty Pharma balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 618.70M | 929.03M | 477.01M | 1.71B | 1.54B | 1.01B | 246.20M | 1.92B |
| Short-Term Investments | 18.80M | 58.20M | 18.30M | 1.30M | 66.00M | 69.98M | 0 | — |
| Total Current Assets | 1.53B | 1.80B | 1.27B | 2.55B | 2.88B | 2.70B | 832.07M | — |
| Goodwill | 924.63M | 0 | — | — | — | — | — | — |
| Intangible Assets | — | — | — | 0 | 5.67M | 28.67M | 51.72M | — |
| Long-Term Investments | 419.00M | 693.50M | 437.10M | 226.30M | 204.40M | 163.02M | 131.28M | — |
| Total Assets | 19.62B | 18.22B | 16.38B | 16.81B | 17.52B | 16.02B | 12.45B | — |
| Accounts Payable | 19.40M | 13.37M | 15.16M | 7.91M | 5.62M | 10.78M | 11.18M | — |
| Short-Term Debt | 380.00M | 997.77M | 0 | 997.51M | 0 | 0 | 281.98M | — |
| Total Current Liabilities | 636.21M | 1.25B | 161.38M | 1.17B | 171.25M | 307.89M | 333.42M | — |
| Long-Term Debt | 8.57B | 6.61B | 6.14B | 6.12B | 7.10B | 5.82B | 5.96B | — |
| Total Liabilities | 9.91B | 7.88B | 6.30B | 7.29B | 7.27B | 6.12B | 6.31B | — |
| Shareholders' Equity | 9.71B | 10.34B | 10.08B | 9.53B | 10.25B | 9.90B | 6.14B | 4.55B |
| Retained Earnings | 2.36B | 2.85B | 2.52B | 1.96B | 2.26B | 1.92B | 2.83B | — |
| Total Debt | 8.95B | 7.61B | 6.14B | 7.12B | 7.10B | 5.82B | 6.24B | — |
| Net Cash (Debt) | -8.31B | -6.63B | -5.64B | -5.40B | -5.49B | -4.74B | -5.99B | 1.92B |
This table shows 8 annual periods of Royalty Pharma's balance sheet, from FY 2025 back to FY 2018, across 16 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow RPRX's reporting calendar. What is a balance sheet?